Fig. 2
From: TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma
Local but not systemic TLR9 activation cooperates with either CTLA-4 or PD-1 blockade to treat B16-F10 melanoma. C57BL/6 J mice were injected with 2.5 × 104 B16-F10 melanoma cells on the right and left flanks. (a) The right flank tumor was then injected with 30μg of the TLR9 agonist ODN1826 or PBS in 50ul on days 3, 6 and 9 or mice received injection of 10μg of the CTLA-4 blocking antibody 9H10 or 10μg of the PD-1 antibody RMP1–14 intra-tumorally. Survival was monitored and mice were euthanized when tumors reached 1000mm3. (b) Tumor growth was measured with calipers for the right (ODN1826 injected) and left (untreated) tumors. (c) As above except that mice received injection of 100μg of the CTLA-4 blocking antibody 9H10 or 250μg of the PD-1 antibody RMP1–14 i.p. Survival was monitored and mice were euthanized when tumors reached 1000mm3. (d) Tumor growth was measured with calipers for the right (ODN1826 injected) and left (untreated) tumors. These data represent one (antibody monotherapies) to two (all combinations) independent experiments of 5–10 mice per group, all mice are shown. Statistical significance was calculated using the log-rank (Mantel-Cox) test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001